Eltchaninoff H, Tron C, Cribier A
Service de cardiologie, hôpital Charles-Nicolle, 1, rue de Germont, 76031 Rouen, France.
Ann Cardiol Angeiol (Paris). 2003 Jun;52(3):198-9. doi: 10.1016/s0003-3928(03)00066-0.
In-stent restenosis remains a limitation of stent implantation. Currently, at the exception of brachytherapy, any percutaneous technique is associated with a high recurrent restenosis rate (> 50%) in diffuse in-stent restenosis. Although based on a small number of patients, eluting stents (sirolimus, paclitaxel) appear promising for the treatment of instent restenosis.
支架内再狭窄仍然是支架植入的一个限制因素。目前，除近距离放射治疗外，任何经皮技术在弥漫性支架内再狭窄中都伴有较高的再狭窄复发率（>50%）。尽管基于少数患者，但洗脱支架（西罗莫司、紫杉醇）在治疗支架内再狭窄方面似乎很有前景。
